Maria Zannes is the founder of BioAffinity Technologies. BioAffinity Technologies has raised $4M in total funding. Latest round: Series A.
Maria Zannes serves as the President and CEO of BioAffinity Technologies, a privately held development-stage company focused on non-invasive, early-stage cancer diagnosis and targeted cancer treatment. The company is commercializing CyPath® Lung, a non-invasive test for early-stage lung cancer, and is also developing diagnostics for other cancers and novel therapeutics. In 2017, BioAffinity Technologies raised over $4 million in Series A funding.
Full founder directory · Investor directory · Company funding database · Fundraising library